ArticleFrontiers in medicine2026

A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target.

Dario Didona et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.